TESAMORELIN - 5mg

Tesamorelin – Synthetic GHRH Analogue Peptide Therapeutic
 
 
Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing hormone (GHRH) that stimulates the body’s endogenous growth hormone (GH) release by binding with high affinity to GHRH receptors in the anterior pituitary. It is a 44-amino-acid polypeptide modified at the N-terminus with a trans-3-hexenoic acid group to improve stability, resistance to enzymatic cleavage, and pharmacokinetics compared with native GHRH. 
 
Technical & chemical data
 
Name: Tesamorelin (INN)  
Brand names: Egrifta SV, Egrifta WR (FDA-approved formulations)  
Structure: 44-amino-acid GHRH analogue with modified N-terminus for enhanced stability  
Molecular weight: ~5 136 Da (polypeptide)  
Routes of administration: Subcutaneous injection (once daily)  
Pharmacokinetics: Short systemic half-life with limited bioavailability; dosing tailored to maintain physiologic GH release patterns  
 
 
Important Notice:
This product is intended for research and investigational use only. Not approved for human or veterinary consumption. All information provided is for educational and research purposes.